Last reviewed · How we verify
CD19 CAR and PD-1 knock out engineered T-cells
CD19 CAR and PD-1 knock out engineered T-cells is a Biologic drug developed by Third Military Medical University. It is currently in Phase 1 development.
At a glance
| Generic name | CD19 CAR and PD-1 knock out engineered T-cells |
|---|---|
| Sponsor | Third Military Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19 CAR and PD-1 knock out engineered T-cells CI brief — competitive landscape report
- CD19 CAR and PD-1 knock out engineered T-cells updates RSS · CI watch RSS
- Third Military Medical University portfolio CI
Frequently asked questions about CD19 CAR and PD-1 knock out engineered T-cells
What is CD19 CAR and PD-1 knock out engineered T-cells?
CD19 CAR and PD-1 knock out engineered T-cells is a Biologic drug developed by Third Military Medical University.
Who makes CD19 CAR and PD-1 knock out engineered T-cells?
CD19 CAR and PD-1 knock out engineered T-cells is developed by Third Military Medical University (see full Third Military Medical University pipeline at /company/third-military-medical-university).
What development phase is CD19 CAR and PD-1 knock out engineered T-cells in?
CD19 CAR and PD-1 knock out engineered T-cells is in Phase 1.